News coverage about Fate Therapeutics (NASDAQ:FATE) has trended somewhat positive on Friday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fate Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.8171711459308 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
FATE has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research report on Thursday, October 12th. Leerink Swann reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research report on Friday, September 8th. Zacks Investment Research lowered Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 6th. ValuEngine lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 7th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $6.79.
Fate Therapeutics (FATE) traded down $0.12 on Friday, hitting $4.15. The stock had a trading volume of 166,500 shares, compared to its average volume of 285,869. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics has a 12-month low of $2.40 and a 12-month high of $5.68.
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.95 million. The company’s revenue for the quarter was up .0% on a year-over-year basis. sell-side analysts forecast that Fate Therapeutics will post -0.99 earnings per share for the current fiscal year.
In related news, insider Daniel D. Shoemaker sold 13,225 shares of Fate Therapeutics stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.87, for a total value of $51,180.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Cindy Tahl sold 8,091 shares of Fate Therapeutics stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.85, for a total value of $31,150.35. The disclosure for this sale can be found here. 10.88% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Fate Therapeutics (FATE) Share Price” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thestockobserver.com/2017/11/24/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-fate-therapeutics-fate-share-price.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.